Comment mettre en place un plateau technique d’aphérèses (notice n° 759759)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05165cam a2200397 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250123101943.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Maurizi-Balzan, Jocelyne |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Comment mettre en place un plateau technique d’aphérèses |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2019.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 39 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Associer la pratique des aphérèses à l’hémodialyse est logique par la gestion des circulations extra-corporelles et dynamise le fonctionnement d’une unité. Les techniques mises en place comprennent échanges plasmatiques thérapeutiques par centrifugation et simple filtration, plasmaphérèse par double filtration et ses dérivés rhéophérèse et LDL aphérèse, immuno-adsorption semi-sélective et spécifique. L’offre de soins est conforme aux recommandations. Un investissement davantage humain que financier est indispensable. Il est récompensé par l’augmentation croissante des demandes issues de différentes spécialités. Les indications et les programmes sont cadrés et accompagnés d’une surveillance clinique et biologique répertoriée par des procédures. Les effets indésirables, dominés par des chutes initiales de pression artérielle, une inflation globale de la volémie, une hypocalcémie, une déperdition de facteurs plasmatiques utiles, des complications induites par les cathéters, sont identifiés, monitorés et maîtrisés. En 2 ans, 1845 séances ont été réalisées pour 134 patients dont 24 pour neuropathies, 12 pour syndrome hémolytique et urémique, 11 pour purpura thrombotique thrombocytopénique, 9 pour vascularites, 5 pour syndrome de Goodpasture, 4 pour artériopathie oblitérante des membres inférieurs, 2 pour myélome, 1 pour hypercholestérolémie. Les 66 autres ont été traités avant ou après une transplantation rénale, pour désimmunisation ABO ou HLA, rejet humoral ou récidive de hyalinose segmentaire et focale. Les résultats obtenus sont en accord avec ceux de la littérature. Ces pratiques, avec peu de décès toujours indépendants des techniques, améliorent quasi constamment le pronostic fonctionnel des patients et l’évolution des pathologies traitées. L’équipe, grâce à un programme reconnu de formation continue, peut, sur place, transmettre les modalités de mise en place et de développement aux soignants intéressés. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Many apheresis techniques can be performed in a blood-bank facility or a hemodialysis (HD) facility. However, it makes sense to perform apheresis in a hemodialysis facility as apheresis involves extra-corporeal circuits and because HD can be performed at the same time as apheresis (tandem procedure). Apheresis techniques comprise therapeutic plasma exchange, double-filtration plasmapheresis, and its derivative (rheopheresis and LDL-apheresis), and immunoadsorption (specific and semi-specific). We have setup an apheresis platform in our hospital that fulfills health recommendations. This process has involved financial investment and significant human resources, and has enabled us to network with different specialties (neurology, hematology, vascular medicine). We have setup protocols according to the type of pathology to be treated by apheresis, and to monitor clinical and biological data for each apheresis session. The main side effects of apheresis are a fall in blood pressure when a session is initiated, an increase in fluid overload, hypocalcemia, and the loss of some essential plasmatic factors. However, these side-effects are easily identified and can be properly managed in real time. Within two-years, we have performed 1845 apheresis sessions (134 patients). Of these, 66 received apheresis before and/or after kidney transplantation for ABO and/or HLA incompatibility (desensitization), for humoral rejection, or in the setting of relapsing focal-segmental glomerulosclerosis. Our patients’ outcomes have been similar to those reported in the literature. The other 68 patients had various conditions. Because our program is now well-established, we are currently forming a specialist center to train physicians and nurses in the various apheresis techniques/procedures. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Hyalinose segmentaire et focale |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Plasmaphérèse par double filtration |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Immuno-adsorption |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Échange plasmatique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Rhéophérèse |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Désimmunisation ABO et HLA |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Focal-segmental glomerulosclerosis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Hemodialysis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ABO and HLA desensitization |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Immunoadsorption |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Plasma exchange |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Double-filtration plasmapheresis |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Jouve, Thomas |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Naciri-Bennani, Hamza |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Noble, Johan |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tanoukhi, Khadija |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Motte, Lionel |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Malvezzi, Paolo |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rostaing, Lionel |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Néphrologie & Thérapeutique | Volume 15 | 6 | 2019-06-26 | p. 439-447 | 1769-7255 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-nephrologie-et-therapeutique-2019-6-page-439?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-nephrologie-et-therapeutique-2019-6-page-439?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux